Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The RAPID Study (NODE-301 Part 2)

Next Previous
Trial Profile

Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia The RAPID Study (NODE-301 Part 2)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etripamil (Primary)
  • Indications Paroxysmal supraventricular tachycardia
  • Focus Registrational; Therapeutic Use
  • Acronyms NODE-301 Part 2; RAPID
  • Sponsors Milestone Pharmaceuticals

Most Recent Events

  • 11 Feb 2025 According to a Milestone Pharmaceuticals media release, company announced that the New Drug Application (NDA) for CARDAMYST is currently under review at the U.S. Food and Drug Administration (FDA). The company expects to launch CARDAMYST in PSVT mid-2025.
  • 29 May 2024 According to a Milestone Pharmaceuticals media release, company announced that the United States Food and Drug Administration (FDA) accepted the Companys New Drug Application (NDA) on May 26, 2024 for CARDAMYST (etripamil) nasal spray, for the management of paroxysmal supraventricular tachycardia (PSVT). The FDA Prescription Drug User Fee Act (PDUFA) target date is 10 months from the acceptance date of May 26, 2024 (27 Mar 2025).
  • 28 Mar 2024 According to a Milestone Pharmaceuticals media release, the company has resubmitted the New Drug Application for etripamil to the U.S. Food and Drug Administration (FDA) for paroxysmal supraventricular tachycardia (PSVT), based on guidance from the FDA obtained in a Type A meeting. The resubmission package included restructured data sets that captured timing of reported AEs and certain data files reformatted to facilitate FDA's analyses. No additional efficacy or safety data were requested.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top